SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-367010
Filing Date
2021-12-27
Accepted
2021-12-27 16:09:31
Documents
12
Period of Report
2021-12-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K d242657d8k.htm   iXBRL 8-K 23941
  Complete submission text file 0001193125-21-367010.txt   149861

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kymr-20211220.xsd EX-101.SCH 2892
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20211220_lab.xml EX-101.LAB 18888
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20211220_pre.xml EX-101.PRE 11860
6 EXTRACTED XBRL INSTANCE DOCUMENT d242657d8k_htm.xml XML 3484
Mailing Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472
Business Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 211520456
SIC: 2836 Biological Products, (No Diagnostic Substances)